Future Perspectives for Antiangiogenic Therapy in Retinal Diseases
The World Health Organization considers eye disorders as the serious problem of our time [1]. According to world statistics, the number of people with visual impairment is 1.3 billion, most of this number are people over 50 years old [2]. Over the past 20 years, developments in the treatment of AMD...
Saved in:
Main Authors: | M. V. Budzinskaya, A. A. Plyukhova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Ophthalmology Publishing Group
2021-10-01
|
Series: | Oftalʹmologiâ |
Subjects: | |
Online Access: | https://www.ophthalmojournal.com/opht/article/view/1634 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New Drugs for the Treatment of DME and the Role of Biomarkers in Predicting Their Effectiveness
by: M. V. Budzinskaya, et al.
Published: (2023-01-01) -
Experience with Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration
by: M. V. Budzinskaya, et al.
Published: (2023-01-01) -
Short-term Outcomes of Anti-VEGF therapy in Neovascular Age-related Macular Degeneration with Initially Low Visual Acuity
by: A. N. Kulikov, et al.
Published: (2025-03-01) -
The Role of Cytokines in Degenerative Retinal Diseases: A Comprehensive Review
by: Rubens Camargo Siqueira, et al.
Published: (2025-07-01) -
Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India
by: Asim K Ghosh, et al.
Published: (2025-06-01)